Amicus Therapeutics Q2 2025 revenue up 18% YoY to $154.7mln.

• Amicus Therapeutics Q2 2025 revenue $154.7M, up 18% at CER • Galafold revenue $128.9M, up 12% at CER • Pombiliti + Opfolda revenue $25.8M, up 58% at CER • Amicus Therapeutics reiterates 2025 financial guidance for GAAP profitability • Conference call and webcast today at 8:30 a.m. ET

Amicus Therapeutics (Nasdaq: FOLD) has released its second-quarter 2025 financial results, showcasing robust growth and continued progress in its rare disease portfolio. The company reported total revenue of $154.7 million, a 18% increase at constant exchange rates (CER) compared to the same period last year. This marks the 17th consecutive quarter of double-digit growth for the biotech firm [1].

Galafold, a key commercial therapy, generated $128.9 million in revenue, representing a 12% increase at CER. Meanwhile, Pombiliti + Opfolda, a newer therapy, contributed $25.8 million in revenue, which was a significant 58% increase at CER. The latter's rapid growth underscores the accelerating adoption of the newer therapy, providing a strong second growth pillar alongside the established Galafold franchise [1].

Despite these positive financials, Amicus reported a GAAP net loss of $24.4 million for the quarter, primarily due to a $30 million upfront payment for licensing DMX-200, a Phase 3 asset for focal segmental glomerulosclerosis (FSGS). Excluding this strategic investment, the company recorded non-GAAP net income of $1.9 million. The company's cash position stood at $231.0 million as of June 30, 2025, providing ample runway as it approaches GAAP profitability in the second half of 2025 [1].

Amicus Therapeutics maintains its 2025 financial guidance, projecting total revenue growth of 15-22%, with Galafold growing 10-15% and Pombiliti + Opfolda increasing 50-65%. The company's pipeline is advancing, with the ACTION3 study of DMX-200 on track to complete enrollment by year-end, which could add a third commercial asset in the medium term. Additionally, Pombiliti + Opfolda received regulatory approval in Japan in June, with up to 10 new launch countries expected in 2025, driving further growth [1].

The company's conference call and webcast to discuss these financial results and corporate updates will take place today at 8:30 a.m. ET [1].

References:

[1] https://www.stocktitan.net/news/FOLD/amicus-therapeutics-announces-second-quarter-2025-financial-results-qja9j5frs1rp.html